Ferring Pharmaceuticals Expands in Parsippany with FDA-Approved Manufacturing Hub

Ferring Pharmaceuticals has officially received FDA approval for its new Drug Product Manufacturing Hub at 100 Interpace Parkway in Parsippany, New Jersey. This 12,000-square-foot facility enhances the company's manufacturing capabilities for ADSTILADRIN, marking it as the third dedicated site for the drug nationwide. The hub is part of a larger 25-acre U. S. Operations Center, which encompasses manufacturing, product development labs, and a training center.

President Aaron Graff noted the company's long-term commitment to the U. S. market and the local community that supports its endeavors. The approval also unlocks a $200 million payment from Royalty Pharma as part of a royalty-based financing agreement established earlier in 2023. Ferring's expansion demonstrates a significant investment in Parsippany's life sciences sector and reinforces New Jersey's reputation as the "Medicine Chest of the World.

" Renewable energy solutions integrated into the facility further showcase Ferring's dedication to sustainability. The company’s growth strategy is supported by its Global Research Center in San Diego.